Pacira's ZILRETTA shoulder OA trial nears readout after enrollment closed
The Phase 3 study finished enrollment in April 2026 and could make ZILRETTA the first approved treatment specifically labeled for shoulder osteoarthritis pain.
Executive Summary
- Pacira has closed enrollment in its registrational trial testing whether an already-approved injectable steroid formulation can extend its label into a joint with no approved on-label drug treatment.
- The trial's completion timeline slipped by more than a year over its life, but enrollment held at target and the study moved cleanly into its follow-up phase without a recruiting shortfall.
- No other industry trial anywhere shares this drug's target in this specific joint indication, so the readout will not confirm or disprove a contested mechanism, it will simply test whether a known drug effect reproduces in a new population.
- Because the comparator arm includes both placebo and an active triamcinolone formulation, the result that would matter most is separation from both, not just from placebo alone.
The trial and the stake
The study, registered as NCT06269705, is testing ZILRETTA against both placebo and an immediate-release triamcinolone acetonide injection in patients with glenohumeral (shoulder) osteoarthritis. The primary endpoint measures the change from baseline in worst daily pain, on a 0-10 scale, at Week 12 for ZILRETTA relative to placebo. Pacira said in its first-quarter 2026 results that it completed enrollment in April 2026 and remains on track for a topline readout later this year, and that a successful result could make ZILRETTA "the first product with an on-label indication for OA pain of the shoulder". NCT06269705+1ZILRETTA in Subjects With Shoulder OsteoarthritisNCT06269705Pacira BioSciences Reports First Quarter 2026 Financial ResultsApr 30, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial design and the bar
The trial is a randomized, active- and placebo-controlled study with two arms, one receiving ZILRETTA and one receiving comparator treatment. Seven secondary endpoints track pain reduction at earlier and later timepoints (Weeks 2, 4, 8, and 18) and compare ZILRETTA against the active triamcinolone arm directly, not only against placebo. That design means the readout carries two distinct bars: a placebo-controlled primary endpoint that supports a label claim, and secondary comparisons against an existing injectable steroid that will show whether the extended-release formulation offers a duration advantage over standard triamcinolone. NCT06269705ZILRETTA in Subjects With Shoulder OsteoarthritisNCT06269705
Operational history
The trial's primary completion date moved twice, from August 2025 to August 2026 and then to December 2026, a cumulative shift of about 16 months from its original date. The anticipated enrollment count was also revised, from 250 down to 150, in November 2025. Enrollment then held flat at 150 through completion, which the trial's own operational baseline treats as a routine, non-flagged variance rather than a shortfall. The study's status moved from Recruiting to Active, not recruiting in May 2026, consistent with enrollment closing as planned. NCT06269705ZILRETTA in Subjects With Shoulder OsteoarthritisNCT06269705
The competitive frame
Searches across trials sharing ZILRETTA's target, NR3C1, or its mechanism class, glucocorticoid receptor agonism, turn up no other industry trial testing that target specifically in shoulder osteoarthritis. The nearest comparators in the shoulder-OA and broader osteoarthritis space, including celecoxib, cannabidiol, and several cell-therapy programs, work through different targets and mechanisms and are not direct comparators to ZILRETTA's biology. ZILRETTA itself is already approved for knee osteoarthritis, so this trial is not testing a new mechanism; it is testing whether an established local corticosteroid effect reproduces in the shoulder joint, where no drug currently carries an on-label indication. PaciraPacira BioSciences Reports First Quarter 2026 Financial ResultsApr 30, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.